The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20010682: Financial Holding Corporation; ORIX Corporation
20010673: The Black & Decker Corporation; Emglo Products, L.P.
Charges for Certain Disclosures - Fair Credit Reporting Act Section 612(a)
0012001 Informal Interpretation
0012002 Informal Interpretation
0012003 Informal Interpretation
0012004 Informal Interpretation
0012005 Informal Interpretation
0012008 Informal Interpretation
0012009 Informal Interpretation
0012010 Informal Interpretation
0012011 Informal Interpretation
20010485: Hollinger Inc.; The James S. Copley Marital Trust
Rules and Regulations Under the Textile Fiber Products Identification Act; Rules and Regulations Under the Wool Products Labeling Act of 1939 - 16 CFR Parts 300 and 303
20010600: Kulicke & Soffa Industries, Inc.; Siegel-Robert, Inc.
20010594: Cox Enterprises, Inc.; Radio One, Inc.
Mylan Laboratories, Inc., Cambrex Corporation, Profarmaco S.R.I., and Gyma Laboratories of America, Inc.
Complaint filed in the U.S. District Court for the District of Columbia charged Mylan with restraint of trade, monopolization and conspiracy to monopolize the market for two generic drugs used to treat anxiety, lorazepam and clorazepate, through exclusive dealing arrangements. The Commission alleged that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. The complaint sought consumer redress of at least $120 million and to enjoin the alleged illegal exclusive licensing agreements. The district court upheld the Commission’s authority to seek restitution in antitrust injunction actions under Section 13(b). The Commission approved a $100 million settlement. The opinion settled Commission concerns that Mylan, Gyma Laboratories of America, Inc., Cambrex Corporation and Profarmaco S.R.L. conspired to deny Mylan’s competitors ingredients necessary to manufacture lorazepam and 40 clorazepate. On Feburary 1, 2002, the court granted approval to a plan of distribution to injured consumers who paid the increased prices and state agencies, including Medicaid programs, that purchased the drugs while the illegal agreements were in effect. The funds were distributed by the states.